Clin2
NCT06762314Possibly a fitRecruiting

Empagliflozin or semaglutide for overweight people with type 1 diabetes

Diabetes

Treatments studied

Part of Hormones & metabolism clinical trials.

This study tests two different medicines (empagliflozin or semaglutide) added to your usual insulin to see if they help with blood sugar control and weight loss in people with type 1 diabetes who are overweight or have obesity. It may be a good fit if your diabetes is not well controlled with insulin injections alone.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
105 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You must have had type 1 diabetes for more than one year.
  • You must be between 18 and 65 years old.
  • Your BMI must be 27 or higher (meaning you are overweight or obese).
  • Your blood sugar control (HbA1c) should be between 7.5% and 10%.
  • You must not use an insulin pump, and you must not have taken certain diabetes medications (like GLP-1 drugs or DPP-4 inhibitors) before.
  • You must not have certain health issues like severe kidney disease, liver problems, history of pancreatitis, or a personal or family history of medullary thyroid cancer.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06909006Not yet recruiting· Phase 3
Semaglutide for type 1 diabetes with higher body weight

This trial tests whether semaglutide (a medicine that helps control blood sugar and weight) can improve outcomes for people with type 1 diabetes who have a higher body weight. It may help if you have had type 1 diabetes for at least 3 years and have a BMI of 30 or more, or 27 or more with a related health problem.

Hillerød, Denmark
NCT07400107Not yet recruiting· Phase 3
Weight loss study for people with type 2 diabetes

This study tests a new medicine called NNC0487-0111 to see how well it helps people with excess body weight and type 2 diabetes lose weight, compared to another medicine called semaglutide. It may be an option if you have type 2 diabetes and are looking to manage your weight.

Hollywood, Florida
NCT06894784Recruiting· Phase 3
Combining two diabetes drugs with an automated insulin pump

This trial tests if adding semaglutide and empagliflozin to your automated insulin delivery system (like a smart pump) can improve blood sugar control for adults with type 1 diabetes. It may help with both glucose levels and weight management.

Montreal, Quebec
NCT07272343Recruiting· Phase 4
Semaglutide vs. diet changes for new type 2 diabetes

This study compares a weekly injection called semaglutide with a calorie-restricted diet to see which helps control blood sugar better. If you have just been diagnosed with type 2 diabetes and have overweight, this trial might help you choose a treatment path.

Jiangxi, Nanchang
NCT06613854Recruiting· Phase 4
Early combination therapy for type 2 diabetes

This study tests if starting two newer diabetes drugs (empagliflozin and semaglutide) soon after diagnosis, along with metformin, helps control blood sugar better than metformin alone. It's for people diagnosed with type 2 diabetes in the last two years who are already taking a high dose of metformin.

Ljubljana
NCT05822609Recruiting· Phase 2
Semaglutide for kidney disease in adults with type 1 diabetes

This Phase 2 study tests semaglutide (a diabetes and weight-related medicine) to see if it can slow or improve diabetic kidney disease in people with type 1 diabetes. You may be able to join if you have type 1 diabetes for at least 5 years and ongoing signs of kidney damage measured in urine tests.

Aurora, Colorado

Hear when a new Diabetes trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.